NATIONAL INSTITUTES OF HEALTH Patent applications |
Patent application number | Title | Published |
20140142137 | HIV INTEGRASE INHIBITORS - Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof. | 05-22-2014 |
20140045950 | DRUG DELIVERY VEHICLE - The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications. | 02-13-2014 |
20130272591 | PHASE SENSITIVE T1 MAPPING IN MAGNETIC RESONANCE IMAGING - Phase sensitive T1 mapping is provided in magnetic resonance (MR). The phase from samples of a modified Look-Locker inversion recovery sequence may be used to normalize contrast, allowing for accurate motion registration without extra information acquisition. The sign may be estimated, allowing T1 mapping with a single application of a non-linear fit. | 10-17-2013 |
20130251726 | NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES - The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided. | 09-26-2013 |
20130217950 | THERAPEUTIC APPARATUS FOR HEATING A SUBJECT - A therapeutic apparatus ( | 08-22-2013 |
20130136697 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES - The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging. | 05-30-2013 |
20130123184 | METHODS FOR INCREASING LEVELS OF HUMAN FETAL HEMOGLOBIN - The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a β-chain hemoglobinopathy including thalassemia (e.g., β-thalassemia) or sickle cell anemia. | 05-16-2013 |
20120301481 | TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS - Immunogenic compositions and methods for eliciting an immune response against | 11-29-2012 |
20120172371 | FLUOROQUINOLONE DERIVATIVES OR SULFONAMIDE MOIETY-CONTAINING COMPOUNDS AS INHIBITORS OF TYROSYL-DNAPHOSPHODIESTERASE (TDP1) - A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor. | 07-05-2012 |
20120115790 | THERAPEUTIC APPROACH TO NEURODEGENERATIVE DISORDERS USING A TFP5-PEPTIDE - Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided. | 05-10-2012 |
20120071356 | Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration - Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided. | 03-22-2012 |
20120003155 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES - A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment. | 01-05-2012 |
20110207141 | DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS - Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed. | 08-25-2011 |
20110165117 | IMMUNOGENIC PEPTIDES AND METHODS OF USE - The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described. | 07-07-2011 |
20110124086 | Hepatitis C Virus Culture System - This disclosure provides compositions and methods for producing infectious hepatitis C virus (HCV). The produced HCV can be infectious in vivo and in vitro. In one aspect, the disclosure provides an immortalized primary hepatocyte transformed with a DNA construct comprising a cDNA sequence of HCV. | 05-26-2011 |
20100286057 | METHODS AND COMPOSITIONS FOR MODULATING BCL-2 FAMILY POLYPEPTIDES - The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the BCL-2 family polypeptide. | 11-11-2010 |
20100021465 | BORIS ISOFORMS AND METHODS OF DETECTING AND TREATING DISEASE - A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same. | 01-28-2010 |
20090311279 | Colorectal Cancer Antigen - A point mutation at position 399 in a commonly expressed gene, designated as COA-1 herein, is diagnostic of colorectal cancer and is capable of eliciting at all mediated immune response. | 12-17-2009 |
20090287036 | Methods And Systems For Using Therapeutic, Diagnostic or Prophylactic Magnetic Agents - Systems and methods are disclosed for directing magnetizable particles comprising therapeutic agents to a target volume, or for guiding magnetizable particles comprising therapeutic agents from a first target volume to a second target volume, at a distance using a magnetic field, to enable the treatment of diseased areas including areas deep inside a patient's body. The methods may be used to diagnose or treat diseased areas within a patient, for example tumors of the lungs, intestines, and liver, and is also useful in enhancing the permeability of solid tumors to chemotherapeutic agents. | 11-19-2009 |
20090176747 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT - The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders. | 07-09-2009 |
20090075296 | METHODS AND COMPOSITIONS FOR ASSAYING REGULATORY T CELLS - Methods and compositions for determining whether a T cell is a regulatory T cell and for determining whether a population of cells includes at least one regulatory T cell or a cell with the potential to become a regulatory T cell. The invention includes methods and compositions for detecting TGF-β on the surface of a cell. The invention also provides methods and compositions for evaluating the suppressive activity of a regulatory T cell based on the presence and/or the amount of membrane-bound TGF-β. | 03-19-2009 |
20080249026 | PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING alpha3beta1 INTEGRINS - The present invention relates to a peptide comprising the sequence R | 10-09-2008 |